SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-21-011984
Filing Date
2021-08-20
Accepted
2021-08-20 16:16:22
Documents
54
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A ruby-20210331x10qa.htm   iXBRL 10-Q/A 1742534
2 EX-31.1 ruby-20210331xex31d1.htm EX-31.1 17932
3 EX-31.2 ruby-20210331xex31d2.htm EX-31.2 17816
4 EX-32.1 ruby-20210331xex32d1.htm EX-32.1 7496
5 EX-32.2 ruby-20210331xex32d2.htm EX-32.2 7458
  Complete submission text file 0001558370-21-011984.txt   5122530

Data Files

Seq Description Document Type Size
6 EX-101.SCH ruby-20210331.xsd EX-101.SCH 30079
7 EX-101.CAL ruby-20210331_cal.xml EX-101.CAL 40263
8 EX-101.DEF ruby-20210331_def.xml EX-101.DEF 89201
9 EX-101.LAB ruby-20210331_lab.xml EX-101.LAB 312805
10 EX-101.PRE ruby-20210331_pre.xml EX-101.PRE 215504
11 EXTRACTED XBRL INSTANCE DOCUMENT ruby-20210331x10qa_htm.xml XML 652305
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-38586 | Film No.: 211193987
SIC: 2836 Biological Products, (No Diagnostic Substances)